DGX Quest Diagnostics
- 149.850
- -0.920-0.61%
- 149.850
- 0.0000.00%
Quest Diagnostics News
Press Release: Quest Diagnostics Declares Quarterly Cash Dividend
Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales
Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
Should Quest Diagnostics (DGX) Be in Your Portfolio Now?
Pregnant Women Undertested for STIs, Finds Quest Diagnostics Health Trends Study of Over 4 Million Pregnancies
Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Financials In Any Way?
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
42 High-quality, Low Beta Stocks to Better 'Sleep at Night' - BofA
Quest Diagnostics Stock Hits 52-week High at $150.66
8 Health Care Stocks With Whale Alerts In Today's Session
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare
Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Seventh Straight Year
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
Quest Diagnostics: Strong Performance and Growth Trajectory Justify Buy Rating
Piper Sandler Adjusts Price Target on Quest Diagnostics to $150 From $145, Maintains Neutral Rating
Quest Diagnostics Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $150
Analysis
Price Target
No Data
